Description: Panel session exploring a variety of issues connected to long-term disability reserve buyouts, including: · Advantages and risks for buyers and sellers · Use of appropriate reserving assumptions · Possible financial structures for a buyout

Description: Cell and Gene Therapy (CGT) are life-changing treatments where conditions such as cancer, hemophilia, spinal muscular atrophy and blindness are being cured. These are great for individuals and society, but the treatment costs are expensive which is bad for payers and reinsurers. This article explores ways for health reinsurance actuaries to participate in the space and evaluate the risk associated with these treatments

Description: This session provides an overview of industry approaches to valuing the liabilities of nontraditional health products. Liabilities for losses that have been incurred but not reported and for losses that have been reported but not paid are examined. Includes a discussion on employer specific stop-loss, provider excess loss, critical illness and cancer insurance. From the Record of the Society of Actuaries, Volume 28, No. 2, Session 133